

Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Owner
Owner
Owner
Owner
Owner
Owner
Contributor
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project leverages a robust dataset (~850,000 single-cell transcriptomes across ages 23–91) to identify differentially expressed genes with very high statistical significance. The targets (e.g., CD38, NR4A1/2, UHRF1, CCR9) are biologically relevant and align with known aging pathways (NAD+ metabolism, epigenetic drift, inflammatory signaling, myeloid skewing). The multi-modal intervention concept—targeting transcriptional stress responses, epigenetic regulation, and protein homeostasis simultaneously—is scientifically rational. However, the score is not a 5 because all evidence remains computational/bioinformatic with zero experimental validation; the mechanistic links between identified gene targets and functional HSC rejuvenation are hypothesized but unproven, and the AubrAI-generated intervention framework, while creative, adds speculative complexity that has not been empirically tested.
Therapeutic Optionality
The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline (immunosenescence), anemia, myelodysplastic syndromes, leukemia prevention, chronic inflammation, and broader regenerative medicine applications. The multi-modal approach (mRNA, siRNA, small molecules, CRISPR, gene therapy, nanoparticle delivery) provides flexibility in intervention modality. Several targets have cross-applicability—CD38 inhibition is already explored in oncology, RhoA/CDC42 modulation has broader regenerative implications, and the platform approach (scRNA-seq + AI/ML target identification) could be extended to other stem cell types. The concept also spans drug repurposing (cromolyn sodium for TPSB2/TPSAB1) and novel drug discovery. A score of 5 is withheld because the optionality is theoretical at this stage and the primary focus remains narrowly on HSCs without demonstrated proof of concept in any therapeutic area.
Intellectual Property
The project has moderate IP potential but also notable risks. On the positive side, the specific combination of targets identified through proprietary computational analysis, the multi-modal temporal intervention protocol, and the use of AI-assisted GRN modeling to prioritize candidates could constitute novel and patentable claims—particularly the specific gene combinations and the phased intervention strategy. The proprietary datasets and computational pipelines add some defensibility. However, several concerns limit the score: (1) No patents have been filed or granted yet—IP advancement is only listed as a future project outcome. (2) Many individual targets (CD38, NR4A1/2, RhoA, mTOR/rapamycin) are well-known in the aging and hematopoiesis literature, creating significant prior art risk. (3) The small molecules proposed (78c, Fasudil, Y-27632, CASIN, rapamycin) are all existing compounds, limiting composition-of-matter claims. (4) The scRNA-seq datasets are partly publicly available, and the analytical methods (GRN modeling, differential expression) are standard in the field. (5) Competition exists from established groups working on HSC aging (e.g., Bhatt, Passegué labs). The IP position would strengthen considerably with experimental validation data and a timely patent filing covering the specific target combinations and intervention protocols.